This Article  • Full text  • PDF  • eFigures  • Interactive Figures  • JAMA Report Video  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Neurogenetics  • Oncology  • Brain Cancer  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Genetics, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Markus Bredel, MD, PhD; Denise M. Scholtens, PhD; Griffith R. Harsh, MD; Claudia Bredel, PhD; James P. Chandler, MD; Jaclyn J. Renfrow, MA; Ajay K. Yadav, PhD; Hannes Vogel, MD, PhD; Adrienne C. Scheck, PhD; Robert Tibshirani, PhD; Branimir I. Sikic, MD

JAMA. 2009;302(3):261-275.

Context  Gliomas, particularly glioblastomas, are among the deadliest of human tumors. Gliomas emerge through the accumulation of recurrent chromosomal alterations, some of which target yet-to-be-discovered cancer genes. A persistent question concerns the biological basis for the coselection of these alterations during gliomagenesis.

Objectives  To describe a network model of a cooperative genetic landscape in gliomas and to evaluate its clinical relevance.

Design, Setting, and Patients  Multidimensional genomic profiles and clinical profiles of 501 patients with gliomas (45 tumors in an initial discovery set collected between 2001 and 2004 and 456 tumors in validation sets made public between 2006 and 2008) from multiple academic centers in the United States and The Cancer Genome Atlas Pilot Project (TCGA).

Main Outcome Measures  Identification of genes with coincident genetic alterations, correlated gene dosage and gene expression, and multiple functional interactions; association between those genes and patient survival.

Results  Gliomas select for a nonrandom genetic landscape—a consistent pattern of chromosomal alterations—that involves altered regions ("territories") on chromosomes 1p, 7, 8q, 9p, 10, 12q, 13q, 19q, 20, and 22q (false-discovery rate–corrected P<.05). A network model shows that these territories harbor genes with putative synergistic, tumor-promoting relationships. The coalteration of the most interactive of these genes in glioblastoma is associated with unfavorable patient survival. A multigene risk scoring model based on 7 landscape genes (POLD2, CYCS, MYC, AKR1C3, YME1L1, ANXA7, and PDCD4) is associated with the duration of overall survival in 189 glioblastoma samples from TCGA (global log-rank P = .02 comparing 3 survival curves for patients with 0-2, 3-4, and 5-7 dosage-altered genes). Groups of patients with 0 to 2 (low-risk group) and 5 to 7 (high-risk group) dosage-altered genes experienced 49.24 and 79.56 deaths per 100 person-years (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.10-2.40; Cox regression model P = .02), respectively. These associations with survival are validated using gene expression data in 3 independent glioma studies, comprising 76 (global log-rank P = .003; 47.89 vs 15.13 deaths per 100 person-years for high risk vs low risk; Cox model HR, 3.04; 95% CI, 1.49-6.20; P = .002) and 70 (global log-rank P = .008; 83.43 vs 16.14 deaths per 100 person-years for high risk vs low risk; HR, 3.86; 95% CI, 1.59-9.35; P = .003) high-grade gliomas and 191 glioblastomas (global log-rank P = .002; 83.23 vs 34.16 deaths per 100 person-years for high risk vs low risk; HR, 2.27; 95% CI, 1.44-3.58; P<.001).

Conclusions  The alteration of multiple networking genes by recurrent chromosomal aberrations in gliomas deregulates critical signaling pathways through multiple, cooperative mechanisms. These mutations, which are likely due to nonrandom selection of a distinct genetic landscape during gliomagenesis, are associated with patient prognosis.

Author Affiliations: Department of Neurological Surgery, Northwestern Brain Tumor Institute, Lurie Center for Cancer Genetics Research and Center for Genetic Medicine (Drs M. Bredel, Chandler, and Yadav and Ms Renfrow), and Department of Preventive Medicine (Dr Scholtens), Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Department of Neurosurgery (Drs M. Bredel and Harsh), Oncology Division, and Departments of Medicine (Drs C. Bredel and Sikic), Pathology (Dr Vogel), and Health Research and Policy and Statistics (Dr Tibshirani), Stanford University School of Medicine, Stanford, California; Department of General Neurosurgery, Neurocenter and Comprehensive Cancer Center Freiburg, University of Freiburg, Freiburg, Germany (Drs M. Bredel and C. Bredel); and Ina Levine Brain Tumor Center, Neuro-Oncology and Neurosurgery Research, Barrow Neurological Institute of St Joseph's Medical Center, Phoenix, Arizona (Dr Scheck).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas
Ajay K. Yadav, Jaclyn J. Renfrow, Denise M. Scholtens, Hehuang Xie, George E. Duran, Claudia Bredel, Hannes Vogel, James P. Chandler, Arnab Chakravarti, Pierre A. Robe, Sunit Das, Adrienne C. Scheck, John A. Kessler, Marcelo B. Soares, Branimir I. Sikic, Griffith R. Harsh, and Markus Bredel
JAMA. 2009;302(3):276-289.
ABSTRACT | FULL TEXT  

One Step Forward Toward Identification of the Genetic Signature of Glioblastomas
Boris Pasche and Richard M. Myers
JAMA. 2009;302(3):325-326.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas
Yadav et al.
JAMA 2009;302:276-289.
ABSTRACT | FULL TEXT  

One Step Forward Toward Identification of the Genetic Signature of Glioblastomas
Pasche and Myers
JAMA 2009;302:325-326.
FULL TEXT